LONDON (Reuters) - Shire's hyperactivity treatment Vyvanse will be available in Europe within months after Britain's drugs regulator backed the amphetamine-based stimulant used to treat millions of U.S. students. The drug, lisdexamfetamine dimesylate, has a slow-release action that activates the amphetamine ingredient over the course of a day, helping levels of alertness and concentration in children with ADHD (attention deficit hyperactivity disorder). It was assessed in Europe under the decentralized approvals procedure, led by Britain's medicines watchdog. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment